MX2023008091A - Soluciones estables de compuestos imidos inmunomoduladores para uso parenteral. - Google Patents

Soluciones estables de compuestos imidos inmunomoduladores para uso parenteral.

Info

Publication number
MX2023008091A
MX2023008091A MX2023008091A MX2023008091A MX2023008091A MX 2023008091 A MX2023008091 A MX 2023008091A MX 2023008091 A MX2023008091 A MX 2023008091A MX 2023008091 A MX2023008091 A MX 2023008091A MX 2023008091 A MX2023008091 A MX 2023008091A
Authority
MX
Mexico
Prior art keywords
parenteral use
stable
stable solutions
solutions
imid
Prior art date
Application number
MX2023008091A
Other languages
English (en)
Inventor
Rod L Hartwig
James Oliver
Arturo Serrano-Batista
Original Assignee
Starton Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starton Therapeutics Inc filed Critical Starton Therapeutics Inc
Publication of MX2023008091A publication Critical patent/MX2023008091A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Se proporcionan composiciones que comprenden una solución estable de un agente de una enfermedad inflamatoria inmunomediada (IMID), como, por ejemplo, un fármaco de imida inmunomoduladora (IMiD) que incluye, entre otros, lenalidomida (LLD). Más particularmente, las modalidades se refiere soluciones estables de IMiD para su uso parenteral. También se proporcionan métodos para preparar soluciones estables de IMiD. En algunas modalidades, se proporcionan métodos para tratar los trastornos inflamatorios y cáncer(es) por medio del uso parenteral de las soluciones de IMiD estables, y las formulaciones de las mismas.
MX2023008091A 2021-01-08 2022-01-07 Soluciones estables de compuestos imidos inmunomoduladores para uso parenteral. MX2023008091A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163135347P 2021-01-08 2021-01-08
PCT/US2022/011572 WO2022150561A1 (en) 2021-01-08 2022-01-07 Stable solutions of immunomodulatory imide compounds for parenteral use

Publications (1)

Publication Number Publication Date
MX2023008091A true MX2023008091A (es) 2023-07-14

Family

ID=80218564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008091A MX2023008091A (es) 2021-01-08 2022-01-07 Soluciones estables de compuestos imidos inmunomoduladores para uso parenteral.

Country Status (9)

Country Link
US (1) US20220218687A1 (es)
EP (1) EP4251131A1 (es)
JP (1) JP2024503001A (es)
KR (1) KR20230129468A (es)
CN (1) CN117098531A (es)
AU (1) AU2022206272A1 (es)
CA (1) CA3204385A1 (es)
MX (1) MX2023008091A (es)
WO (1) WO2022150561A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020263285A1 (en) * 2019-04-22 2021-10-28 Starton Therapeutics, Inc. Continuous delivery of lenalidomide and other immunomodulatory agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN101336890A (zh) * 2008-05-30 2009-01-07 济南基福医药科技有限公司 一种抗癌缓释凝胶注射剂
CA2774015A1 (en) * 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof
US9724329B2 (en) * 2010-06-21 2017-08-08 Peter Maccallum Cancer Institute Stimulating immune response
US20120208755A1 (en) * 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2016378482A1 (en) * 2015-12-22 2018-07-12 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
CN109310624A (zh) * 2016-06-15 2019-02-05 托伦特药物有限公司 阿普斯特的局部组合物
WO2018089829A1 (en) * 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
AU2020263285A1 (en) * 2019-04-22 2021-10-28 Starton Therapeutics, Inc. Continuous delivery of lenalidomide and other immunomodulatory agents

Also Published As

Publication number Publication date
JP2024503001A (ja) 2024-01-24
KR20230129468A (ko) 2023-09-08
WO2022150561A1 (en) 2022-07-14
AU2022206272A1 (en) 2023-07-27
CN117098531A (zh) 2023-11-21
EP4251131A1 (en) 2023-10-04
US20220218687A1 (en) 2022-07-14
CA3204385A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
US11932643B2 (en) Substituted heterocyclic inhibitors of PTPN11
US20210196695A1 (en) K-ras modulators
US20200048249A1 (en) Ptpn11 inhibitors
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
MX2022005053A (es) Inhibidores de peque?as moleculas de mutante g12c de kras.
RU2463298C2 (ru) Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения
CR20230066A (es) Agonistas del glp-1 heterocíclicos
MA34604B1 (fr) Derives de la pyrazine en tant que bloqueurs de l'enac
CR20200403A (es) Macrociclos como moduladores del regular de conductancia transmenbrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosisquística y procesos para elaborarlos
US10246462B2 (en) Chemokine receptor modulators and uses thereof
CR20220371A (es) Agonistas heterocíclicos de glp-1
HRP20050967B8 (hr) Derivati pirazolo-kinazolina, postupak njihovog dobivanja i njihova uporaba kao inhibitora kinaze
CN112218850A (zh) 整合应激通路的调节剂
MX2019011530A (es) Saxitoxinas 11,13-modificadas para el tratamiento del dolor.
MX2007003327A (es) Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
UA84175C2 (ru) Гетероциклические ингибиторы мэк и их применение
CA2493225A1 (en) Quinoline derivatives and their use as mycobacterial inhibitors
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
CN102612367A (zh) 脯氨酰羟化酶抑制剂
MA30487B1 (fr) Nouveaux composes heterocycliques
MX2023008091A (es) Soluciones estables de compuestos imidos inmunomoduladores para uso parenteral.
EP2785707A1 (en) Novel 2h-indazoles as ep2 receptor antagonists
PH12020551494A1 (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
MX2022010219A (es) Compuestos heterociclicos de heteroarilo y usos de los mismos.
MX2022000598A (es) Preparacion de compuestos antibacterianos.